WO2004047872A3 - Treatment of neurodegenerative disease through intracranial delivery of short interfering rna (sirna) - Google Patents
Treatment of neurodegenerative disease through intracranial delivery of short interfering rna (sirna) Download PDFInfo
- Publication number
- WO2004047872A3 WO2004047872A3 PCT/US2003/037650 US0337650W WO2004047872A3 WO 2004047872 A3 WO2004047872 A3 WO 2004047872A3 US 0337650 W US0337650 W US 0337650W WO 2004047872 A3 WO2004047872 A3 WO 2004047872A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- interfering rna
- disease
- catheter
- sirna
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03790026A EP1569662A2 (en) | 2002-11-26 | 2003-11-26 | Treatment of neurodegenerative disease through intracranial delivery of short interfering rna (sirna) |
AU2003293035A AU2003293035A1 (en) | 2002-11-26 | 2003-11-26 | Treatment of neurodegenerative disease through intracranial delivery of short interfering rna (sirna) |
CA002507606A CA2507606A1 (en) | 2002-11-26 | 2003-11-26 | Treatment of neurodegenerative disease through intracranial delivery of short interfering rna (sirna) |
JP2005510322A JP4868854B2 (en) | 2002-11-26 | 2003-11-26 | Treatment of neurodegenerative diseases through intracranial delivery of siRNA |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42938702P | 2002-11-26 | 2002-11-26 | |
US60/429,387 | 2002-11-26 | ||
US44461403P | 2003-02-03 | 2003-02-03 | |
US60/444,614 | 2003-02-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004047872A2 WO2004047872A2 (en) | 2004-06-10 |
WO2004047872A3 true WO2004047872A3 (en) | 2005-02-03 |
Family
ID=32397198
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/037650 WO2004047872A2 (en) | 2002-11-26 | 2003-11-26 | Treatment of neurodegenerative disease through intracranial delivery of short interfering rna (sirna) |
Country Status (7)
Country | Link |
---|---|
US (2) | US7605249B2 (en) |
EP (4) | EP1569662A2 (en) |
JP (2) | JP4868854B2 (en) |
AT (1) | ATE550025T1 (en) |
AU (1) | AU2003293035A1 (en) |
CA (1) | CA2507606A1 (en) |
WO (1) | WO2004047872A2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8957198B2 (en) | 2003-02-03 | 2015-02-17 | Medtronic, Inc. | Compositions, devices and methods for treatment of Huntington's disease through intracranial delivery of sirna |
US9133517B2 (en) | 2005-06-28 | 2015-09-15 | Medtronics, Inc. | Methods and sequences to preferentially suppress expression of mutated huntingtin |
US9260716B2 (en) | 2002-08-05 | 2016-02-16 | University Of Iowa Research Foundation | RNA interference suppression of neurodegenerative diseases and methods of use thereof |
US9273356B2 (en) | 2006-05-24 | 2016-03-01 | Medtronic, Inc. | Methods and kits for linking polymorphic sequences to expanded repeat mutations |
US9375440B2 (en) | 2006-11-03 | 2016-06-28 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
US9487779B2 (en) | 2002-08-05 | 2016-11-08 | University Of Iowa Research Foundation | siRNA-mediated gene silencing |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040096880A1 (en) * | 2001-08-07 | 2004-05-20 | Kmiec Eric B. | Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation |
EP1423537A4 (en) * | 2001-08-07 | 2006-11-29 | Univ Delaware | Compositions and methods for the prevention and treatment of huntington's disease |
US20050106731A1 (en) * | 2002-08-05 | 2005-05-19 | Davidson Beverly L. | siRNA-mediated gene silencing with viral vectors |
US20050255086A1 (en) * | 2002-08-05 | 2005-11-17 | Davidson Beverly L | Nucleic acid silencing of Huntington's Disease gene |
US20050042646A1 (en) | 2002-08-05 | 2005-02-24 | Davidson Beverly L. | RNA interference suppresion of neurodegenerative diseases and methods of use thereof |
US7618948B2 (en) | 2002-11-26 | 2009-11-17 | Medtronic, Inc. | Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA |
US7829694B2 (en) * | 2002-11-26 | 2010-11-09 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US7605249B2 (en) * | 2002-11-26 | 2009-10-20 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
AU2003301030A1 (en) * | 2002-12-17 | 2004-07-22 | Victor Miller | Sirna-mediated gene silencing |
US7732591B2 (en) * | 2003-11-25 | 2010-06-08 | Medtronic, Inc. | Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna |
CA2526893C (en) * | 2003-05-14 | 2010-10-26 | Japan Science And Technology Agency | Inhibition of the expression of huntingtin gene |
US7595306B2 (en) * | 2003-06-09 | 2009-09-29 | Alnylam Pharmaceuticals Inc | Method of treating neurodegenerative disease |
CA2542232A1 (en) * | 2003-06-09 | 2005-01-20 | Alnylam Pharmaceuticals, Inc. | Method for treating neurodegenerative disease by inhibiting alpha-synuclein |
ES2485848T3 (en) * | 2003-09-12 | 2014-08-14 | University Of Massachusetts | RNA interference for the treatment of disorders related to function gain |
US8680063B2 (en) * | 2003-09-12 | 2014-03-25 | University Of Massachusetts | RNA interference for the treatment of gain-of-function disorders |
WO2005045034A2 (en) * | 2003-10-23 | 2005-05-19 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED TREATMENT OF PARKINSON DISEASE USING SHORT INTERERING NUCLEIC ACID (siNA) |
US20050208090A1 (en) * | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
US7872117B2 (en) * | 2004-03-26 | 2011-01-18 | Van Andel Research Institute | c-met siRNA adenovirus vectors inhibit cancer cell growth, invasion and tumorigenicity |
WO2005105995A2 (en) * | 2004-04-14 | 2005-11-10 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED TREATMENT OF POLYGLUTAMINE (POLYQ) REPEAT EXPANSION DISEASES USING SHORT INTERFERING NUCLEIC ACID (siNA) |
JP2008503590A (en) * | 2004-06-21 | 2008-02-07 | メドトロニック・インコーポレーテッド | Medical systems and methods for delivering compositions to cells |
CA2580189C (en) | 2004-09-29 | 2013-05-21 | Children's Memorial Hospital | Sirna-mediated gene silencing of alpha synuclein |
CA2596588C (en) * | 2005-01-31 | 2017-06-27 | University Of Iowa Research Foundation | Nucleic acid silencing of huntington's disease gene |
US7902352B2 (en) * | 2005-05-06 | 2011-03-08 | Medtronic, Inc. | Isolated nucleic acid duplex for reducing huntington gene expression |
WO2007002904A2 (en) * | 2005-06-28 | 2007-01-04 | Medtronic, Inc. | Methods and sequences to preferentially suppress expression of mutated huntingtin |
US20070161591A1 (en) * | 2005-08-18 | 2007-07-12 | University Of Massachusetts | Methods and compositions for treating neurological disease |
GB0610183D0 (en) * | 2006-05-23 | 2006-06-28 | Isis Innovation | Treatment of neurodegenerative diseases |
WO2008134646A2 (en) | 2007-04-26 | 2008-11-06 | University Of Iowa Research Foundation | Rna interference suppression of neurodegenerative diseases and methods of use thereof |
WO2008143774A2 (en) * | 2007-05-01 | 2008-11-27 | University Of Massachusetts | Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy |
WO2008150897A2 (en) | 2007-05-31 | 2008-12-11 | University Of Iowa Research Foundation | Reduction of off-target rna interference toxicity |
WO2011087804A2 (en) | 2009-12-21 | 2011-07-21 | Medtronic, Inc. | Peptide-polynucleotide compositions, and methods for transfecting a cell with dna and treatment of neurodegenerative disease |
WO2011133658A1 (en) | 2010-04-22 | 2011-10-27 | Boston Medical Center Corporation | Compositions and methods for targeting and delivering therapeutics into cells |
CA2827380C (en) | 2011-02-12 | 2020-08-25 | University Of Iowa Research Foundation | Therapeutic nucleic acids |
NZ625980A (en) * | 2012-01-04 | 2015-05-29 | Quark Pharmaceuticals Inc | Double-stranded rna compounds to casp2 and uses thereof |
SG11201507496UA (en) | 2013-04-17 | 2015-11-27 | Pfizer | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
US10006027B2 (en) | 2014-03-19 | 2018-06-26 | Ionis Pharmaceuticals, Inc. | Methods for modulating Ataxin 2 expression |
CN106103717A (en) * | 2014-03-19 | 2016-11-09 | Ionis制药公司 | For regulating the compositions that ataxin 2 is expressed |
WO2015171370A1 (en) | 2014-05-05 | 2015-11-12 | Medtronic, Inc. | Methods and compositions for scd, crt, crt-d, or sca therapy identification and/or selection |
EP3146051B8 (en) | 2014-05-20 | 2019-11-27 | University of Iowa Research Foundation | Huntington's disease therapeutic compounds |
US11207461B2 (en) | 2015-07-30 | 2021-12-28 | Anoop U. R | Drug delivery system and method for controlled and continuous delivery of drugs into the brain by bypassing the blood brain barrier |
WO2017075335A1 (en) | 2015-10-28 | 2017-05-04 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
JP7444521B2 (en) * | 2015-12-01 | 2024-03-06 | スパーク セラピューティクス インコーポレイテッド | A scalable method for producing recombinant adeno-associated virus (AAV) vectors in a serum-free suspension cell culture system suitable for clinical use. |
EP3448431A4 (en) * | 2016-04-26 | 2020-01-01 | Saint Louis University | Highly selective adenosine a3 receptor subtype agonsists for the prevention and treatment of neurodegenerative disorders |
JOP20190104A1 (en) * | 2016-11-10 | 2019-05-07 | Ionis Pharmaceuticals Inc | Compounds and methods for reducing atxn3 expression |
WO2019028306A2 (en) | 2017-08-03 | 2019-02-07 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
AU2018352236A1 (en) | 2017-10-16 | 2020-04-23 | The Curators Of The University Of Missouri | Treatment of amyotrophic lateral sclerosis (ALS) |
TW202015742A (en) | 2018-05-15 | 2020-05-01 | 美商航海家醫療公司 | Compositions and methods for delivery of aav |
JP2021523914A (en) | 2018-05-15 | 2021-09-09 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | Compositions and Methods for Treating Parkinson's Disease |
WO2019222441A1 (en) | 2018-05-16 | 2019-11-21 | Voyager Therapeutics, Inc. | Aav serotypes for brain specific payload delivery |
EP3793615A2 (en) | 2018-05-16 | 2021-03-24 | Voyager Therapeutics, Inc. | Directed evolution of aav to improve tropism for cns |
JP7379387B2 (en) | 2018-06-05 | 2023-11-14 | エフ. ホフマン-ラ ロシュ アーゲー | Oligonucleotides for controlling ATXN2 expression |
US20210361318A1 (en) | 2018-07-02 | 2021-11-25 | Voyager Therapeutics, Inc. | Cannula system and use thereof |
CA3103963A1 (en) | 2018-07-02 | 2020-01-09 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord |
MX2021000810A (en) | 2018-07-24 | 2021-04-28 | Voyager Therapeutics Inc | Systems and methods for producing gene therapy formulations. |
WO2020023737A1 (en) | 2018-07-25 | 2020-01-30 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing atxn2 expression |
WO2020072849A1 (en) | 2018-10-04 | 2020-04-09 | Voyager Therapeutics, Inc. | Methods for measuring the titer and potency of viral vector particles |
US20210371470A1 (en) | 2018-10-12 | 2021-12-02 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
SG11202107645RA (en) | 2019-01-18 | 2021-08-30 | Voyager Therapeutics Inc | Methods and systems for producing aav particles |
US11286485B2 (en) | 2019-04-04 | 2022-03-29 | Hoffmann-La Roche Inc. | Oligonucleotides for modulating ATXN2 expression |
US20220251564A1 (en) * | 2019-04-19 | 2022-08-11 | Sorbonne Universite | p16INK4a INHIBITOR FOR PREVENTING OR TREATING HUNTINGTON'S DISEASE |
JP2022545378A (en) * | 2019-08-15 | 2022-10-27 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | Therapies combining transgene and intron-derived miRNAs for the treatment of SCA1 |
US20220333133A1 (en) | 2019-09-03 | 2022-10-20 | Voyager Therapeutics, Inc. | Vectorized editing of nucleic acids to correct overt mutations |
CA3180222A1 (en) | 2020-04-15 | 2021-10-21 | Voyager Therapeutics, Inc. | Tau binding compounds |
CA3181546A1 (en) | 2020-05-01 | 2021-11-04 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating atxn1 |
CN116096734A (en) | 2020-05-13 | 2023-05-09 | 沃雅戈治疗公司 | Redirection of tropism of AAV capsids |
WO2022132923A1 (en) | 2020-12-16 | 2022-06-23 | Voyager Therapeutics, Inc. | Tau binding compounds |
WO2022187548A1 (en) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
WO2022206821A1 (en) * | 2021-03-30 | 2022-10-06 | 南京大学 | Rna delivery system for treating parkinson's disease |
WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
WO2023070057A1 (en) * | 2021-10-21 | 2023-04-27 | Switch Therapeutics Inc. | Condition-activatable nucleic acid constructs and their uses for treating neurological diseases |
WO2023081648A1 (en) | 2021-11-02 | 2023-05-11 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
WO2023091948A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
CN114259502A (en) * | 2021-12-24 | 2022-04-01 | 南京鼓楼医院 | Method for central targeting delivery of siRNA based on adipose tissue and application |
WO2023154693A1 (en) | 2022-02-08 | 2023-08-17 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
WO2023230282A1 (en) * | 2022-05-25 | 2023-11-30 | The General Hospital Corporation | Modulation of bace1 as a therapy for spinocerebellar ataxia |
WO2023235791A1 (en) | 2022-06-02 | 2023-12-07 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
WO2023250388A1 (en) | 2022-06-22 | 2023-12-28 | Voyager Therapeutics, Inc. | Tau binding compounds |
WO2024006741A1 (en) | 2022-06-28 | 2024-01-04 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
WO2024011112A1 (en) | 2022-07-06 | 2024-01-11 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
WO2024030976A2 (en) | 2022-08-03 | 2024-02-08 | Voyager Therapeutics, Inc. | Compositions and methods for crossing the blood brain barrier |
WO2024059739A1 (en) | 2022-09-15 | 2024-03-21 | Voyager Therapeutics, Inc. | Tau binding compounds |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997040874A1 (en) * | 1996-04-30 | 1997-11-06 | Medtronic, Inc. | Techniques of treating neurodegenerative disorders by brain infusion |
WO2001049844A1 (en) * | 1999-12-30 | 2001-07-12 | Rutgers, The State University Of New Jersey | Compositions and methods for gene silencing |
WO2001091801A2 (en) * | 2000-05-26 | 2001-12-06 | Chiron Corporation | Methods of transducing neural cells using lentivirus vectors |
US6468524B1 (en) * | 2000-03-22 | 2002-10-22 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | AAV4 vector and uses thereof |
WO2003047676A1 (en) * | 2001-11-30 | 2003-06-12 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by brain infusion of mutational vectors |
WO2003070895A2 (en) * | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Inc. | RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2003099298A1 (en) * | 2002-05-24 | 2003-12-04 | Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. | Rna interference mediating small rna molecules |
Family Cites Families (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4965188A (en) * | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
GB2181691B (en) | 1985-10-21 | 1990-05-23 | Porvair Ltd | Gloves |
US4800159A (en) * | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US5702716A (en) | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
CA2109955A1 (en) | 1991-05-24 | 1992-11-26 | Toru Hayakawa | Equipment for intracerebral administration of preparations |
US5236908A (en) | 1991-06-07 | 1993-08-17 | Gensia Pharmaceuticals, Inc. | Methods of treating injury to the central nervous system |
JPH08500481A (en) | 1992-05-11 | 1996-01-23 | リボザイム・ファーマシューティカルズ・インコーポレーテッド | Methods and agents for inhibiting viral replication |
EP1251170A3 (en) | 1992-07-17 | 2002-10-30 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of NF-kappaB dependent animal diseases |
US5354326A (en) * | 1993-01-27 | 1994-10-11 | Medtronic, Inc. | Screening cable connector for interface to implanted lead |
CA2116280A1 (en) * | 1993-03-05 | 1994-09-06 | Marcy E. Macdonald | Huntingtin dna, protein and uses thereof |
DE69430824T2 (en) | 1993-08-12 | 2003-01-23 | Neurotech Sa | Biocompatible immunoisolatory capsules that contain genetically modified cells |
WO1995005864A1 (en) * | 1993-08-27 | 1995-03-02 | Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | Convection-enhanced drug delivery |
US5624803A (en) * | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
WO1995016774A1 (en) * | 1993-12-17 | 1995-06-22 | Spinal Cord Society | Method for inducing dna synthesis in neurons |
ATE386131T1 (en) * | 1994-04-13 | 2008-03-15 | Univ Rockefeller | AAV-MEDIATED DELIVERY OF DNA INTO CELLS OF THE NERVOUS SYSTEM |
US6294202B1 (en) | 1994-10-06 | 2001-09-25 | Genzyme Corporation | Compositions containing polyanionic polysaccharides and hydrophobic bioabsorbable polymers |
AU4412096A (en) | 1994-12-13 | 1996-07-03 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses |
US5534350A (en) | 1994-12-28 | 1996-07-09 | Liou; Derlin | Powerfree glove and its making method |
AU5545596A (en) * | 1995-04-28 | 1996-11-18 | Medtronic, Inc. | Intraparenchymal infusion catheter system |
US7069634B1 (en) * | 1995-04-28 | 2006-07-04 | Medtronic, Inc. | Method for manufacturing a catheter |
US5840059A (en) | 1995-06-07 | 1998-11-24 | Cardiogenesis Corporation | Therapeutic and diagnostic agent delivery |
US5942455A (en) | 1995-11-14 | 1999-08-24 | Drexel University | Synthesis of 312 phases and composites thereof |
JPH09268067A (en) | 1996-03-29 | 1997-10-14 | Asahi Glass Co Ltd | Production of silicon carbide member |
WO2000062828A1 (en) | 1996-04-30 | 2000-10-26 | Medtronic, Inc. | Autologous fibrin sealant and method for making the same |
US5976109A (en) | 1996-04-30 | 1999-11-02 | Medtronic, Inc. | Apparatus for drug infusion implanted within a living body |
US7189222B2 (en) * | 1996-04-30 | 2007-03-13 | Medtronic, Inc. | Therapeutic method of treatment of alzheimer's disease |
US6281009B1 (en) * | 1996-09-11 | 2001-08-28 | The General Hospital Corporation | Use of a non-mammalian DNA virus to express an exogenous gene in a mammalian cell |
US5882561A (en) | 1996-11-22 | 1999-03-16 | Drexel University | Process for making a dense ceramic workpiece |
GB9701684D0 (en) * | 1997-01-28 | 1997-03-19 | Smithkline Beecham Plc | Novel compounds |
US5968059A (en) | 1997-03-06 | 1999-10-19 | Scimed Life Systems, Inc. | Transmyocardial revascularization catheter and method |
GB9706463D0 (en) * | 1997-03-27 | 1997-05-14 | Medical Res Council | A model of inflamation in the central nervous system for use in the study of disease |
US6436708B1 (en) | 1997-04-17 | 2002-08-20 | Paola Leone | Delivery system for gene therapy to the brain |
US5931861A (en) * | 1997-04-25 | 1999-08-03 | Medtronic, Inc. | Medical lead adaptor having rotatable locking clip mechanism |
US5782892A (en) * | 1997-04-25 | 1998-07-21 | Medtronic, Inc. | Medical lead adaptor for external medical device |
US6042579A (en) * | 1997-04-30 | 2000-03-28 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain |
US6110459A (en) | 1997-05-28 | 2000-08-29 | Mickle; Donald A. G. | Transplants for myocardial scars and methods and cellular preparations |
US20050282198A1 (en) | 1997-05-29 | 2005-12-22 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype |
US6187906B1 (en) * | 1997-08-11 | 2001-02-13 | Aukland Uniservices Limited | Methods to improve neural outcome |
US6231969B1 (en) | 1997-08-11 | 2001-05-15 | Drexel University | Corrosion, oxidation and/or wear-resistant coatings |
US6376471B1 (en) * | 1997-10-10 | 2002-04-23 | Johns Hopkins University | Gene delivery compositions and methods |
US6151525A (en) | 1997-11-07 | 2000-11-21 | Medtronic, Inc. | Method and system for myocardial identifier repair |
US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
JP3012923B2 (en) * | 1998-01-26 | 2000-02-28 | 新潟大学長 | Drug for treating CAG repeat disease |
DE19938960A1 (en) | 1998-03-10 | 2001-02-22 | Bisping Hans Juergen | Test cable connecting probe to test apparatus, e.g. for testing implanted pacemaker, electrotherapy or electro-diagnostics includes crocodile clip and flexible conductor with spring contact |
AUPP249298A0 (en) * | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
WO1999050300A1 (en) | 1998-03-30 | 1999-10-07 | The Trustees Of The University Of Pennsylvania | Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders |
US6436392B1 (en) * | 1998-05-20 | 2002-08-20 | University Of Iowa Research Foundation | Adeno-associated virus vectors |
ATE435917T1 (en) | 1998-05-27 | 2009-07-15 | Genzyme Corp | AAV VECTORS FOR PRODUCING THE DRUGS FOR CONVECTION-ENHANCED ADMINISTRATION |
US6313268B1 (en) * | 1998-10-16 | 2001-11-06 | Vivian Y. H. Hook | Secretases related to Alzheimer's dementia |
US6245884B1 (en) * | 1998-10-16 | 2001-06-12 | Vivian Y. H. Hook | Secretases related to alzheimer's dementia |
US6319905B1 (en) * | 1998-12-29 | 2001-11-20 | Cell Genesys, Inc. | Method of controlling L-Dopa production and of treating dopamine deficiency |
US6835194B2 (en) | 1999-03-18 | 2004-12-28 | Durect Corporation | Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners |
WO2000065042A1 (en) | 1999-04-28 | 2000-11-02 | The Board Of Trustees Of The Leland Stanford Junior University | P element derived vector and methods for its use |
US6310058B1 (en) * | 1999-05-27 | 2001-10-30 | University Of Notre Dame Du Lac | Antimycobacterial agents |
WO2001016312A2 (en) | 1999-08-31 | 2001-03-08 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid based modulators of gene expression |
GB9928248D0 (en) | 1999-12-01 | 2000-01-26 | Gill Steven S | An implantable guide tube for neurosurgery |
US6310048B1 (en) | 1999-12-09 | 2001-10-30 | St. Louis University | Antisense modulation of amyloid beta protein expression |
US6461989B1 (en) | 1999-12-22 | 2002-10-08 | Drexel University | Process for forming 312 phase materials and process for sintering the same |
US20030092003A1 (en) | 1999-12-29 | 2003-05-15 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of Alzheimer's disease |
WO2002081628A2 (en) | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
US20050032733A1 (en) | 2001-05-18 | 2005-02-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA) |
MXPA02008361A (en) | 2000-02-28 | 2004-05-17 | Genesegues Inc | Nanocapsule encapsulation system and method. |
US6945969B1 (en) | 2000-03-31 | 2005-09-20 | Medtronic, Inc. | Catheter for target specific drug delivery |
US6551290B1 (en) * | 2000-03-31 | 2003-04-22 | Medtronic, Inc. | Catheter for target specific drug delivery |
US6372250B1 (en) | 2000-04-25 | 2002-04-16 | The Regents Of The University Of California | Non-invasive gene targeting to the brain |
US20020042388A1 (en) | 2001-05-01 | 2002-04-11 | Cooper Mark J. | Lyophilizable and enhanced compacted nucleic acids |
AU2001288317A1 (en) * | 2000-08-30 | 2002-03-13 | Agion Technologies, Llc | Bi-laminar, hyaluronan coatings with silver-based anti-microbial properties |
US20050209179A1 (en) | 2000-08-30 | 2005-09-22 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) |
US6659995B1 (en) | 2000-11-17 | 2003-12-09 | Syde A. Taheri | Autologous myocyte micro granual retrieval and implantation (AMMGRI) |
CA2327208A1 (en) | 2000-11-30 | 2002-05-30 | The Government Of The United States Of America | Methods of increasing distribution of therapeutic agents |
DK2813582T3 (en) | 2000-12-01 | 2017-07-31 | Max-Planck-Gesellschaft Zur Förderung Der Wss E V | Small RNA molecules that mediate RNA interference |
MXPA03006006A (en) * | 2001-01-03 | 2005-02-14 | Johnson & Johnson | Alpha synuclein aggregation assays. |
CA2438832A1 (en) * | 2001-02-23 | 2002-09-06 | Elan Pharmaceuticals, Inc. | Transgenic knockouts of bace-1 |
US7182944B2 (en) | 2001-04-25 | 2007-02-27 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of increasing distribution of nucleic acids |
US20030095958A1 (en) | 2001-04-27 | 2003-05-22 | Bhisetti Govinda R. | Inhibitors of bace |
AU2002320100A1 (en) | 2001-06-15 | 2003-01-02 | Interleukin Genetics, Inc. | Methods for detecting and treating the early onset of aging-related conditions |
EP1423537A4 (en) | 2001-08-07 | 2006-11-29 | Univ Delaware | Compositions and methods for the prevention and treatment of huntington's disease |
US6944497B2 (en) | 2001-10-31 | 2005-09-13 | Medtronic, Inc. | System and method of treating stuttering by neuromodulation |
WO2003042996A1 (en) * | 2001-11-13 | 2003-05-22 | Sae Magnetics (H.K.) Ltd. | Universal fixture for hsa assembly and its testing process |
US20030120282A1 (en) | 2001-12-24 | 2003-06-26 | Scouten Charles W. | Stereotaxic manipulator with retrofitted linear scales and digital display device |
US7294504B1 (en) | 2001-12-27 | 2007-11-13 | Allele Biotechnology & Pharmaceuticals, Inc. | Methods and compositions for DNA mediated gene silencing |
US7270653B2 (en) | 2002-02-20 | 2007-09-18 | Abbott Research Group | Methods of treating abnormal biological conditions using metal oxides |
US20050096284A1 (en) | 2002-02-20 | 2005-05-05 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
US20030224512A1 (en) | 2002-05-31 | 2003-12-04 | Isis Pharmaceuticals Inc. | Antisense modulation of beta-site APP-cleaving enzyme expression |
US20040023855A1 (en) | 2002-04-08 | 2004-02-05 | John Constance M. | Biologic modulations with nanoparticles |
US20040018520A1 (en) | 2002-04-22 | 2004-01-29 | James Thompson | Trans-splicing enzymatic nucleic acid mediated biopharmaceutical and protein |
US7008403B1 (en) | 2002-07-19 | 2006-03-07 | Cognitive Ventures Corporation | Infusion pump and method for use |
US7148342B2 (en) * | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
AU2002368132A1 (en) | 2002-07-25 | 2004-02-16 | Nissei Kabushiki Kaisha | Roll cone manufacturing device |
US20050255086A1 (en) | 2002-08-05 | 2005-11-17 | Davidson Beverly L | Nucleic acid silencing of Huntington's Disease gene |
US20040023390A1 (en) | 2002-08-05 | 2004-02-05 | Davidson Beverly L. | SiRNA-mediated gene silencing with viral vectors |
US20050042646A1 (en) | 2002-08-05 | 2005-02-24 | Davidson Beverly L. | RNA interference suppresion of neurodegenerative diseases and methods of use thereof |
EP2305813A3 (en) | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
US20040265849A1 (en) | 2002-11-22 | 2004-12-30 | Applera Corporation | Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof |
US7605249B2 (en) * | 2002-11-26 | 2009-10-20 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US7829694B2 (en) | 2002-11-26 | 2010-11-09 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US20050048641A1 (en) | 2002-11-26 | 2005-03-03 | Medtronic, Inc. | System and method for delivering polynucleotides to the central nervous system |
JP2004232811A (en) | 2003-01-31 | 2004-08-19 | Hitachi Unisia Automotive Ltd | Electromagnetic clutch for driving auxiliary machine |
US8946151B2 (en) | 2003-02-24 | 2015-02-03 | Northern Bristol N.H.S. Trust Frenchay Hospital | Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen |
US8512290B2 (en) | 2003-03-20 | 2013-08-20 | Boston Scientific Scimed, Inc. | Devices and methods for delivering therapeutic or diagnostic agents |
US20040186528A1 (en) | 2003-03-20 | 2004-09-23 | Medtronic, Inc. | Subcutaneous implantable medical devices with anti-microbial agents for chronic release |
US20040198640A1 (en) | 2003-04-02 | 2004-10-07 | Dharmacon, Inc. | Stabilized polynucleotides for use in RNA interference |
SI1620133T1 (en) | 2003-05-01 | 2016-03-31 | Genzyme Corporation | Gene therapy for neurometabolic disorders |
US20040258666A1 (en) | 2003-05-01 | 2004-12-23 | Passini Marco A. | Gene therapy for neurometabolic disorders |
US7917228B2 (en) | 2003-05-13 | 2011-03-29 | Medtronic, Inc. | Medical lead adaptor assembly |
US20060014165A1 (en) | 2003-07-14 | 2006-01-19 | Decode Genetics Ehf. | Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association |
ES2485848T3 (en) | 2003-09-12 | 2014-08-14 | University Of Massachusetts | RNA interference for the treatment of disorders related to function gain |
WO2005065242A2 (en) | 2003-12-29 | 2005-07-21 | Am Biosolutions | Method of treating cancer using platelet releasate |
US20050153353A1 (en) | 2004-01-09 | 2005-07-14 | Bernd Meibohm | Real-time polymerase chain reaction-based genotyping assay for beta2-adrenergic receptor single nucleotide polymorphism |
US20050202075A1 (en) | 2004-03-12 | 2005-09-15 | Pardridge William M. | Delivery of genes encoding short hairpin RNA using receptor-specific nanocontainers |
US20050260202A1 (en) * | 2004-03-19 | 2005-11-24 | The Regents Of The University Of California | Methods for producing proliferating muscle cells |
WO2005116204A1 (en) | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same |
AU2005202624A1 (en) | 2004-06-28 | 2006-01-12 | Lifescan Scotland Limited | Resealable vial and dispensing mechanism for test sensor |
WO2006022639A1 (en) | 2004-07-21 | 2006-03-02 | Applera Corporation | Genetic polymorphisms associated with alzheimer's disease, methods of detection and uses thereof |
WO2006047250A2 (en) | 2004-10-22 | 2006-05-04 | Neurologix, Inc. | Use of apoptosis inhibiting compounds in degenerative neurological disorders |
NL1028134C2 (en) | 2005-01-27 | 2006-07-31 | Sara Lee De Nv | Method for preparing a drink suitable for consumption from at least two ingredients to be dissolved and / or extracted and an amount of liquid. |
TW200635542A (en) | 2005-04-01 | 2006-10-16 | Dharma Drum Mountain | Method of establishing and using commemorative material |
US20060257912A1 (en) | 2005-05-06 | 2006-11-16 | Medtronic, Inc. | Methods and sequences to suppress primate huntington gene expression |
US20080280843A1 (en) | 2006-05-24 | 2008-11-13 | Van Bilsen Paul | Methods and kits for linking polymorphic sequences to expanded repeat mutations |
GB0520235D0 (en) | 2005-10-05 | 2005-11-16 | Astrazeneca Ab | Method |
EP2325315B1 (en) | 2005-10-28 | 2014-05-07 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of huntingtin gene |
US20080039415A1 (en) | 2006-08-11 | 2008-02-14 | Gregory Robert Stewart | Retrograde transport of sirna and therapeutic uses to treat neurologic disorders |
CN200970210Y (en) | 2006-10-12 | 2007-11-07 | 王会才 | Cleaning and dewatering machine for mop |
-
2003
- 2003-11-25 US US10/721,693 patent/US7605249B2/en not_active Expired - Fee Related
- 2003-11-26 EP EP03790026A patent/EP1569662A2/en not_active Withdrawn
- 2003-11-26 AT AT09013626T patent/ATE550025T1/en active
- 2003-11-26 CA CA002507606A patent/CA2507606A1/en not_active Abandoned
- 2003-11-26 EP EP07003775A patent/EP1829547A3/en not_active Withdrawn
- 2003-11-26 WO PCT/US2003/037650 patent/WO2004047872A2/en active Application Filing
- 2003-11-26 AU AU2003293035A patent/AU2003293035A1/en not_active Abandoned
- 2003-11-26 EP EP09013626A patent/EP2145628B1/en not_active Expired - Lifetime
- 2003-11-26 JP JP2005510322A patent/JP4868854B2/en not_active Expired - Fee Related
- 2003-11-26 EP EP07003774A patent/EP1832292A1/en not_active Withdrawn
-
2009
- 2009-08-27 US US12/549,110 patent/US8119611B2/en not_active Expired - Fee Related
-
2011
- 2011-07-25 JP JP2011162422A patent/JP2012006938A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997040874A1 (en) * | 1996-04-30 | 1997-11-06 | Medtronic, Inc. | Techniques of treating neurodegenerative disorders by brain infusion |
WO2001049844A1 (en) * | 1999-12-30 | 2001-07-12 | Rutgers, The State University Of New Jersey | Compositions and methods for gene silencing |
US6468524B1 (en) * | 2000-03-22 | 2002-10-22 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | AAV4 vector and uses thereof |
WO2001091801A2 (en) * | 2000-05-26 | 2001-12-06 | Chiron Corporation | Methods of transducing neural cells using lentivirus vectors |
WO2003047676A1 (en) * | 2001-11-30 | 2003-06-12 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by brain infusion of mutational vectors |
WO2003070895A2 (en) * | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Inc. | RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2003099298A1 (en) * | 2002-05-24 | 2003-12-04 | Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. | Rna interference mediating small rna molecules |
Non-Patent Citations (10)
Title |
---|
AEBISCHER P ET AL: "Recombinant proteins for neurodegenerative diseases: the delivery issue", TRENDS IN NEUROSCIENCE, ELSEVIER, AMSTERDAM, NL, vol. 24, no. 9, 1 September 2001 (2001-09-01), pages 533 - 540, XP004298585, ISSN: 0166-2236 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2003, HOMMEL J D ET AL: "Local gene knockdown in the brain using viral - mediated RNA interference ( RNAi ).", XP002278731, Database accession no. PREV200400198119 * |
DAVIDSON B L ET AL: "MOLECULAR MEDICINE FOR THE BRAIN: SILENCING OF DISEASE GENES WITH RNA INTERFERENCE", LANCET NEUROLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 3, no. 3, March 2004 (2004-03-01), pages 145 - 149, XP001180651, ISSN: 1474-4422 * |
GLORIOSO J C ET AL: "Use of HSV vectors to modify the nervous system", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT 2002 UNITED KINGDOM, vol. 5, no. 2, 2002, pages 289 - 295, XP002278729, ISSN: 1367-6733 * |
GOTO J ET AL: "SUPPRESSION OF HUNTINGTIN GENE EXPRESSION BY SIRNA: A POSSIBLE THERAPEUTIC TOOL FOR HUNTINGTON'S DISEASE", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, vol. 60, no. 5, SUPPL 1, 11 March 2003 (2003-03-11), pages A286, XP009029181, ISSN: 0028-3878 * |
MCMANUS M T ET AL: "Gene silencing in mammals by small interfering RNAs", NATURE REVIEWS GENETICS, MACMILLAN MAGAZINES, GB, vol. 3, October 2002 (2002-10-01), pages 737 - 747, XP002973403 * |
MILLER VICTOR M ET AL: "Allele-specific silencing of dominant disease genes.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 100, no. 12, 10 June 2003 (2003-06-10), June 10, 2003, pages 7195 - 7200, XP002278730, ISSN: 0027-8424 (ISSN print) * |
NALDINI L ET AL: "EFFICIENT TRANSFER, INTEGRATION, AND SUSTAINED LONG-TERM EXPRESSIONOF THE TRANSGENE IN ADULT RAT BRAINS INJECTED WITH A LENTIVIRAL VECTOR", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 93, October 1996 (1996-10-01), pages 11382 - 11388, XP002917173, ISSN: 0027-8424 * |
SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 2003, 2003, 33rd Annual Meeting of the Society of Neuroscience;New Orleans, LA, USA; November 08-12, 2003, pages Abstract No. 325.14 * |
XIA H ET AL: "siRNA-mediated gene silencing in vitro and in vivo", NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 20, no. 10, October 2002 (2002-10-01), pages 1006 - 1010, XP002251054, ISSN: 1087-0156 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9260716B2 (en) | 2002-08-05 | 2016-02-16 | University Of Iowa Research Foundation | RNA interference suppression of neurodegenerative diseases and methods of use thereof |
US9487779B2 (en) | 2002-08-05 | 2016-11-08 | University Of Iowa Research Foundation | siRNA-mediated gene silencing |
US8957198B2 (en) | 2003-02-03 | 2015-02-17 | Medtronic, Inc. | Compositions, devices and methods for treatment of Huntington's disease through intracranial delivery of sirna |
US9133517B2 (en) | 2005-06-28 | 2015-09-15 | Medtronics, Inc. | Methods and sequences to preferentially suppress expression of mutated huntingtin |
US9273356B2 (en) | 2006-05-24 | 2016-03-01 | Medtronic, Inc. | Methods and kits for linking polymorphic sequences to expanded repeat mutations |
US9375440B2 (en) | 2006-11-03 | 2016-06-28 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
Also Published As
Publication number | Publication date |
---|---|
JP2006515864A (en) | 2006-06-08 |
EP2145628B1 (en) | 2012-03-21 |
ATE550025T1 (en) | 2012-04-15 |
US20040162255A1 (en) | 2004-08-19 |
US7605249B2 (en) | 2009-10-20 |
EP1569662A2 (en) | 2005-09-07 |
EP2145628A1 (en) | 2010-01-20 |
US20100063134A1 (en) | 2010-03-11 |
WO2004047872A2 (en) | 2004-06-10 |
CA2507606A1 (en) | 2004-06-10 |
US8119611B2 (en) | 2012-02-21 |
EP1832292A1 (en) | 2007-09-12 |
AU2003293035A1 (en) | 2004-06-18 |
JP4868854B2 (en) | 2012-02-01 |
JP2012006938A (en) | 2012-01-12 |
EP1829547A3 (en) | 2007-09-12 |
AU2003293035A8 (en) | 2004-06-18 |
EP1829547A2 (en) | 2007-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004047872A3 (en) | Treatment of neurodegenerative disease through intracranial delivery of short interfering rna (sirna) | |
WO2005116212A3 (en) | Treatment of neurodegenerative disease through intracranial delivery of sirna | |
WO2008021149A3 (en) | Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna | |
WO2007022506A3 (en) | Methods and compositions for treating neurological disease | |
WO2003013437A3 (en) | Compositions and methods for the prevention and treatment of huntington's disease | |
GB2463833A (en) | Methods and compositions for the treatment of neurological disorders | |
TW200510458A (en) | Humanized antibodies that recognize beta amyloid peptide | |
MXPA03010843A (en) | Use of azetidinone substituted derivatives in the treatment of alzheimer's disease. | |
WO2003057916A3 (en) | Cancer profiles | |
WO2007133812A3 (en) | Improved carriers for delivery of nucleic acid agents to cells and tissues | |
WO2005006945A3 (en) | Methods for treating neural disorders and compounds useful therefor | |
WO2007141346A3 (en) | Genes regulating intracellular cholesterol trafficking as targets for treatment of cholesterol-related diseases | |
EP2402443A3 (en) | Therapeutic uses of inhibitors of rtp801 | |
TW200420550A (en) | Thiazole compounds for the treatment of neurodegenerative disorders | |
WO2006048450A3 (en) | Peptides for use in the treating obesity | |
DE69936785D1 (en) | CELL-AGGRAVATED GENETIC ADMINISTRATION THROUGH THE USE OF MUSCLES DERIVED FROM MUSCLES FOR THE TREATMENT OF BONE-RELATED INJURY OR DISORDER | |
WO2005030200A8 (en) | Remedy for autoimmune diseases | |
WO2006083797A3 (en) | Improving and protecting cell therapy for neurological disorders including parkinson's disease | |
HK1131745A1 (en) | Neurotoxic oligomers | |
TW200628473A (en) | Novel heterocycles | |
WO2003027068A3 (en) | Substituted amines for the treatment of neurological disorders | |
WO2005037832A3 (en) | Azabicycyclic compounds for relieving pain and treating central nervous system disorders | |
WO2008157787A3 (en) | Hydroxylated tolans and related compounds in the treatment of cancer | |
WO2002077172A3 (en) | Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-il8 and anti-muc18 in diverse types of tumors | |
WO2005003103A3 (en) | 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2507606 Country of ref document: CA Ref document number: 2005510322 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003790026 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003790026 Country of ref document: EP |